National Stock Exchange of India Limited  
Listing department, Exchange Plaza, 
Bandra- Kurla Complex, Bandra (E)  
mumbai- 400 051  
Scrip Symbol: IRFC

BSE Limited  
Listing Dept / Dept of Corporate Services,  
PJ Towers, Dalal Street,  
mumbai -400 001  
Scrip Code: 543257

Sub: Newspaper Advertisement- Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sir/ Madam,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find enclosed Newspaper Clipping of the advertisement published in English and regional (Hindi) newspaper(s).

This is submitted for your information and record.

Thanking You,

For Indian Railway Finance Corporation Limited

(Vijay Babulal Shirode)  
Company Secretary & Compliance Officer

Enclosure: As Above
Corbevax gets nod as third dose after Covishield, Covaxin

The health ministry has approved Biological E’s Covid-19 vaccine, Corbevax, as the third shot after two doses of Covishield or Covaxin for all adults, clearing the decks for the first heterologous booster in India.

So far, India was using the same vaccine as the third dose after two doses of Covishield (Covid-19 vaccine made by Serum Institute of India) or Covaxin (manufactured by Bharat Biotech). This is the first time India has allowed mixing vaccine types.

According to a source, Corbevax will be administered as a booster shot six months after two doses of Covishield or Covaxin for all adults. Necessary changes to the Co-WIN portal are expected to be made within a week’s time.

The approval comes after recommendations made in recent weeks by the National Technical Advisory Group (NTAGI) that had reviewed data submitted by Biological E (BE) and the Drugs Controller General of India (DCGI) had okayed Corbevax as a heterologous booster on June 3.

‘Recently, BE has furnished its clinical data to the DCGI which, after a detailed evaluation and deliberations with Subject Experts Committee, granted approval for administering Corbevax as a heterologous booster dose to people who have already taken two doses of either Covishield or Covaxin,’ a health ministry statement data that the Corbevax booster dose provided evidence of a significant increase in immune response and excellent safety profile required for an effective booster dose, the company had said in June after it received the DCGI nod.

BE has conducted a multi-centre Phase III placebo controlled heterologous booster clinical trial in 416 subjects aged 18-80 years, who had been vaccinated with two doses of either Covishield or Covaxin at least six months prior to the administration of Corbevax.

The company had said in June that the Corbevax booster dose increased the neutralising antibody titers by 60-70 fold compared to the plaques. There were no issues on adverse events of interest for three months after follow-up after the booster dose was administered, it added.

A subset of subjects evaluated for neutralising antibodies (nAbs) against Omicron showed that the Corbevax booster resulted in a significant increase in the Ado titers against the coronavirus variant. After the booster dose of Corbevax, Omicron-specific indices were observed in 91 per cent and 75 per cent of subjects who had previously received primary vaccines followed by two doses of Covishield or Covaxin, respectively, the company had said.

The booster dose of Corbevax, Omicron-specific indices were observed in 91 per cent and 75 per cent of subjects who had previously received primary vaccines followed by two doses of Covishield or Covaxin, respectively, the company had said.

The approval comes after recommendations made in recent weeks by the National Technical Advisory Group (NTAGI) that had reviewed data submitted by Biological E (BE) and the Drugs Controller General of India (DCGI) had okayed Corbevax as a heterologous booster on June 3.

Corbevax gets nod as third dose after Covishield, Covaxin

You can say that CAPITAL GAINS!

You might have heard about indirect capital gains and capital indexed gains, which offset the capital gains of the property you sell and generate indexed gains as well. Now, there’s a new type of gain called ‘capital gains on shares’.

In the context of capital gains, you are in possession of a long-term share, it will be necessary to understand the new concept of ‘capital gains on shares’.

Corbevax gets nod as third dose after Covishield, Covaxin

You can say that CAPITAL GAINS!

You might have heard about indirect capital gains and capital indexed gains, which offset the capital gains of the property you sell and generate indexed gains as well. Now, there’s a new type of gain called ‘capital gains on shares’.

In the context of capital gains, you are in possession of a long-term share, it will be necessary to understand the new concept of ‘capital gains on shares’.

Corbevax gets nod as third dose after Covishield, Covaxin

You can say that CAPITAL GAINS!

You might have heard about indirect capital gains and capital indexed gains, which offset the capital gains of the property you sell and generate indexed gains as well. Now, there’s a new type of gain called ‘capital gains on shares’.

In the context of capital gains, you are in possession of a long-term share, it will be necessary to understand the new concept of ‘capital gains on shares’.

Corbevax gets nod as third dose after Covishield, Covaxin

You can say that CAPITAL GAINS!
### VRL Logistics Limited

**Regd. Office:** Rs. No. 351/1, Vasant Vihar, New Delhi, 110057

**Company Secretary:** Mr. S. K. Verma, B.Com., CSINO (F) 122, CSIPA, CMA (I)

**Designated Director:** Mr. S. K. Verma, B.Com., CSINO (F) 122, CSIPA, CMA (I)

**Registrar:** Rajeshwar Coop. Bank Ltd., 2nd Floor, 120, Aurobindo Marg, New Delhi - 110012

### EXTRACT OF STATEMENT OF REVISED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2022

<table>
<thead>
<tr>
<th>Particulars</th>
<th>June 30, 2022</th>
<th>March 31, 2021</th>
<th>March 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Turnover</td>
<td>7,00,00,000</td>
<td>6,50,00,000</td>
<td>6,00,00,000</td>
</tr>
<tr>
<td><strong>Profit Before Tax</strong></td>
<td>3,00,000</td>
<td>2,50,000</td>
<td>2,00,000</td>
</tr>
<tr>
<td><strong>Profit After Tax</strong></td>
<td>2,00,000</td>
<td>1,50,000</td>
<td>1,00,000</td>
</tr>
</tbody>
</table>

**Notes:**
1. The above financial results have been reviewed by the Audit Committee and approved and later reviewed by the Board of Directors of the Company.
2. The Company has reported a net profit for the quarter ended 31st March 2022. The profit after tax for the quarter ended 31st March 2021 and 31st March 2020 is due to a one-time gain on the de-recognition of subsidiary companies.
3. The Company has reported an increase in the overall turnover for the quarter ended 31st March 2022 as compared to the quarter ended 31st March 2021 and 31st March 2020.

**Author:** Mr. S. K. Verma

---

**LARGEST FLEET 5036 COMPANY OWNED VEHICLES!**

- Containerized vehicles
- General Parcel - Part Truck Load & Full Truck Load services
- Varied & Unique B2B customer base
- Hub & Spoke model for effective consignment delivery
- Presence in 23 States and 4 Union Territories
- Growth Capex - Orders placed for 1600 additional high capacity trucks
- Aggressive Network expansion - 10 new branch added in Q1'22 & 91 branches added during FY 22
Metal & Mining Stocks to Face Headwinds as China’s Export Glut Weighs on Prices

Lower prices to dent realisations and margins: Tata Steel, JSW Steel, Hindalco still top picks

Jagan Vanapalli

While China’s labour and metal overcapacity has been a known issue for some time, the current glut in the industry has been exacerbated by a variety of factors, including a slowdown in global demand and a surge in supply. This has put pressure on prices and margins for metal producers in India, particularly those with significant exposure to the domestic market.

Tata Steel, JSW Steel, and Hindalco are some of the companies that are likely to be impacted by this trend. With demand slowing, these companies will have to adjust their pricing strategies to ensure they can maintain their margins.

For Tata Steel, the company has already taken steps to reduce costs and improve efficiency. However, it remains to be seen how effective these measures will be in the current market environment.

JSW Steel, on the other hand, has been focusing on expanding its overseas operations to diversify its revenue streams. This strategy may help the company to mitigate some of the pressure from falling domestic prices.

Hindalco, too, has been looking to overseas markets to reduce its dependence on the domestic market. However, the company will need to be careful not to overexpose itself to foreign markets, given the uncertainty around global demand.

Overall, the metal industry is expected to face a challenging year ahead, with lower prices and margins likely to be the norm.

Indian Railway Finance Corporation Limited

Exhibit of Statement of Unaudited Financial Results for the quarter ended 30 June 2022

<table>
<thead>
<tr>
<th>Particulars</th>
<th>30 June 2022</th>
<th>30 June 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue Turnover</td>
<td>(in Rs. crore)</td>
<td>(in Rs. crore)</td>
</tr>
<tr>
<td>Profit Before Tax</td>
<td>(in Rs. crore)</td>
<td>(in Rs. crore)</td>
</tr>
<tr>
<td>Profit After Tax</td>
<td>(in Rs. crore)</td>
<td>(in Rs. crore)</td>
</tr>
<tr>
<td>Earnings Per Share (Basic)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Notes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
एयरपोर्ट पर विमान के नीचे नहीं चुराएँ बाहरी
बाद में वर्षाकाल की कारण में नमका जा रहा असरधार दृष्टि, विकल्प को चुराने की से बहुत ज्यादा बढ़ती है।

जॉन से आत्मक हमले की आरंभ
परास्त, नगरीय के अनुसार होने का नाम कुरान दिया जाना कुरान

700 हेक्टेयर की हामी बाँक, परियोजनाओं ने किया हंगामा
नकनिंग होम में गर्भवती की हुई मौत, परियोजनाओं ने किया हंगामा

बुजुर्ग ने दिया था सहारा लूट और हत्या कर फरार
बुजुर्ग ने दिया था सहारा लूट और हत्या कर फरार

शंघाउँ के दोनों तरीकों में सैन्य मिश्रण से लिपली महिला, मौत नहीं दिखाई पड़ी
शंघाउँ के दोनों तरीकों में सैन्य मिश्रण से लिपली महिला, मौत नहीं दिखाई पड़ी
महिलाओं के विकास आयोग में 17.5 प्रतिशत की कटौती

3 जनवरी | 11 अगस्त, 2022

महिलाओं के विकास आयोग में 17.5 प्रतिशत की कटौती

**नोट्स:**
1. Total Income from Operations (Net) 3.63 27.10 81.54 219.46
2. Net Profit/Loss for the period (before tax, Exceptional and /or Extraordinary Items)

**MOONGIPA SECURITIES LTD**
(CIN: L74190UP1999PLC025868)
Registered Office: 35, Budjarpur, City Centre, Greater Noida 201301, Uttar Pradesh
E-mail: info@moongipa.com
Website: www.moongipa.com

**EXTRACT OF THE STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2022**

<table>
<thead>
<tr>
<th>Periods</th>
<th>Egps (EPAT)</th>
<th>Egps (EPAT)</th>
<th>Egps (EPAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 June 2022</td>
<td>1.60/1.71</td>
<td>1.50/1.61</td>
<td>3.32/3.43</td>
</tr>
<tr>
<td>30 June 2021</td>
<td>1.20/1.31</td>
<td>1.10/1.21</td>
<td>2.80/2.91</td>
</tr>
<tr>
<td>30 June 2020</td>
<td>0.80/0.91</td>
<td>0.70/0.81</td>
<td>2.30/2.41</td>
</tr>
</tbody>
</table>

**NOTES:**
1. The above results are not audited. The results for the quarter ended 30th June, 2022 have been reviewed by the Audit Committee and are in accordance with the provisions of the Companies Act, 2013 and Rules issued thereunder.
2. The above results are subject to the results of the General Meeting of the Company to be held on 31st August, 2022. The complete format of the above results is available on the Stock Exchange website (www.bseindia.com) and company’s website (www.moongipa.com).

**Alliance Integrated Metals Ltd**
(CIN: L27200MH1987PLC66032)
Registered Office: 35, Budjarpur, City Centre, Greater Noida 201301, Uttar Pradesh
E-mail: info@moongipa.com
Website: www.moongipa.com

**MOONGIPA SECURITIES LTD**
(CIN: L74190UP1999PLC025868)
Registered Office: 35, Budjarpur, City Centre, Greater Noida 201301, Uttar Pradesh
E-mail: info@moongipa.com
Website: www.moongipa.com

**EXTRACT OF THE STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2022**

<table>
<thead>
<tr>
<th>Periods</th>
<th>Egps (EPAT)</th>
<th>Egps (EPAT)</th>
<th>Egps (EPAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 June 2022</td>
<td>1.60/1.71</td>
<td>1.50/1.61</td>
<td>3.32/3.43</td>
</tr>
<tr>
<td>30 June 2021</td>
<td>1.20/1.31</td>
<td>1.10/1.21</td>
<td>2.80/2.91</td>
</tr>
<tr>
<td>30 June 2020</td>
<td>0.80/0.91</td>
<td>0.70/0.81</td>
<td>2.30/2.41</td>
</tr>
</tbody>
</table>

**NOTES:**
1. The above results are not audited. The results for the quarter ended 30th June, 2022 have been reviewed by the Audit Committee and are in accordance with the provisions of the Companies Act, 2013 and Rules issued thereunder.
2. The above results are subject to the results of the General Meeting of the Company to be held on 31st August, 2022. The complete format of the above results is available on the Stock Exchange website (www.bseindia.com) and company’s website (www.moongipa.com).